Search

Your search keyword '"Elbaz, Tamer"' showing total 27 results
Start Over Author "Elbaz, Tamer" Publication Year Range Last 3 years
27 results on '"Elbaz, Tamer"'

12. Egyptian Society of Liver Cancer Recommendation Guidelines for the Management of Hepatocellular Carcinoma [Corrigendum]

Author

Omar, Ashraf, primary, Kaseb, Ahmed, additional, Elbaz, Tamer, additional, El-Kassas, Mohamed, additional, El Fouly, Amr, additional, Hanno, Abdel Fatah, additional, El Dorry, Ahmed, additional, Hosni, Ahmed, additional, Helmy, Amr, additional, Saad, Amr S, additional, Alolayan, Ashwaq, additional, Eysa, Basem, additional, Hamada, Emad, additional, Azim, Hamdy, additional, Khattab, Hany, additional, Elghazaly, Hesham, additional, Tawfik, Hesham, additional, Ayoub, Hisham, additional, Khaled, Hussein, additional, Saadeldin, Ibtessam, additional, Waked, Imam, additional, Barakat, Eman, additional, El Meteini, Mahmoud, additional, Hamed Shaaban, Mohamed, additional, EzzElarab, Mohamed, additional, Fathy, Mohamed, additional, Shaker, Mohamed, additional, Sobhi, Mohamed, additional, ElGharib, Mohamed, additional, Abdullah, Mohammed, additional, Mokhtar, Mohesn, additional, Elshazli, Mostafa, additional, Heikal, Omar, additional, Hetta, Osama, additional, ElWakil, Reda, additional, Abdel Wahab, Sameh, additional, Eid, Samir, additional, and Rostom, Yousri, additional

Published
2023
Full Text
View/download PDF

14. PD-L1 small molecule inhibitors and Paclitaxel orchestrating CD8+ cell cytotoxicity via tumor-associated macrophages: a personalized HCC immunotherapeutic approach

Author

Helal, Israa, primary, Kamal, Monica A., additional, Ramadan, Ahmed, additional, Elbaz, Tamer, additional, Nabeel, Mohamed Mahmoud, additional, Elfishawi, Sally, additional, Shousha, Hend Ibrahim, additional, Omar, Ashraf, additional, Mandour, Yasmine M., additional, and El Tayebi, Hend, additional

Published
2023
Full Text
View/download PDF

17. Role of Transient Elastography (Fibroscan) in Early prediction of Hepatitis C Virus Related Hepatocellular Carcinoma

Author

Allah, Mohammed N. Abou Hia, primary, Abdelaziz, Ashraf O., additional, Al-Nadry, Mohammed H., additional, Gomaa, Walid M., additional, Abdel-Halim, Mohamed M., additional, Nabeel, Mohamed M., additional, elbaz, Tamer M., additional, Lithy, Rania, additional, Abdelmaksoud, Ahmed hosni, additional, and Shousha, Hend I., additional

Published
2023
Full Text
View/download PDF

18. Assessment of circulating levels of microRNA-326, microRNA-424, and microRNA-511 as biomarkers for hepatocellular carcinoma in Egyptians

Author

Youssef, Samar Samir, primary, El fiky, Asmaa, additional, Nabeel, Mohamed M, additional, Shousha, Hend Ibrahim, additional, Elbaz, Tamer, additional, Omran, Dalia, additional, Marie, Mohammad Saeed, additional, Elzahry, Mohammad A, additional, Abul-Fotouh, Amr, additional, Hashem, Ahmed, additional, Guda, Mohamed F, additional, and Abdelaziz, Ashraf O, additional

Published
2022
Full Text
View/download PDF

19. Role of endoscopic ultrasound and cyst fluid tumor markers in diagnosis of pancreatic cystic lesions

Author

Okasha, Hussein Hassan, primary, Abdellatef, Abeer, additional, Elkholy, Shaimaa, additional, Mogawer, Mohamad-Sherif, additional, Yosry, Ayman, additional, Elserafy, Magdy, additional, Medhat, Eman, additional, Khalaf, Hanaa, additional, Fouad, Magdy, additional, Elbaz, Tamer, additional, Ramadan, Ahmed, additional, Behiry, Mervat E, additional, William, Kerolis Y, additional, Habib, Ghada, additional, Kaddah, Mona, additional, Abdel-Hamid, Haitham, additional, Abou-Elmagd, Amr, additional, Galal, Ahmed, additional, Abbas, Wael A, additional, Altonbary, Ahmed Youssef, additional, El-Ansary, Mahmoud, additional, Abdou, Aml E, additional, Haggag, Hani, additional, Abdellah, Tarek Ali, additional, Elfeki, Mohamed A, additional, Faheem, Heba Ahmed, additional, Khattab, Hani M, additional, El-Ansary, Mervat, additional, Beshir, Safia, additional, and El-Nady, Mohamed, additional

Published
2022
Full Text
View/download PDF

24. Schistosoma mansoni infection and the occurrence, characteristics, and survival of patients with hepatocellular carcinoma: an observational study over a decade.

Author

Shousha, Hend Ibrahim, Abdelaziz, Ashraf Omar, Nabeel, Mohamed Mahmoud, Omran, Dalia Abdelhamid, Abdelmaksoud, Ahmed Hosni, Elbaz, Tamer Mahmoud, Salah, Ayman, Harb, Shady Tarek ElGhazaly, Hosny, Karim Adel, Osman, Ayman, Atef, Mira, Gaber, Abdelazez, Zayed, Naglaa Ali, Yosry, Ayman Abdelhady, and Leithy, Rania

Subjects
HEPATOCELLULAR carcinoma, HEPATITIS C virus, SCHISTOSOMIASIS, SCHISTOSOMA mansoni, ANTIVIRAL agents
Abstract

Schistosoma mansoni infection (SMI) is suspected to be directly and indirectly involved in hepato-carcinogenesis. This study evaluated the association of a previous SMI with hepatocellular carcinoma (HCC) development, patients, tumor characteristics, treatment outcomes, and survival. This observational study included patients with HCC with and without previous SMI who presented to the multidisciplinary HCC clinic, Kasr-Alainy hospital (November 2009 to December 2019). It also included 313 patients with liver cirrhosis without HCC. Clinical and laboratory features of the patients (complete blood count, liver/renal functions , alpha-fetoprotein, and hepatitis B/C status), tumor characteristics (Triphasic CT and/or dynamic MRI), liver stiffness (transient elastography), HCC treatment outcome, and overall survival were studied. This study included 1446 patients with HCC; 688(47.6%) composed group-1, defined by patients having a history of SMI, and 758(52.4%) were in group-2 and without history of SMI. Male sex, smoking, diabetes mellitus, splenomegaly, deteriorated performance status, synthetic liver functions, and platelet count were significantly higher in group-1. The groups did not differ with regard to liver stiffness, tumor characteristics, or the occurrence of post-HCC treatment hepatic decompensation or recurrence. HCC treatment response was better in group-2. Group-1 showed lower sustained virological response to hepatitis C direct-acting antivirals (DAAs) compared with group-2 (60% versus 84.3%, respectively, P = 0.027). Prior SMI was associated with HCC (adjusted odds ratio = 1.589, 95% confidence interval = 1.187–2.127), and it was concluded that it increases the risk of HCC. In addition, it significantly affects the performance status, laboratory characteristics, response to DAAs, and overall survival. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

25. Efficacy of combined Sofosbuvir and Daclatasvir in the treatment of COVID-19 patients with pneumonia: a multicenter Egyptian study.

Author

El-Bendary, Mahmoud, Abd-Elsalam, Sherief, Elbaz, Tamer, El-Akel, Wafaa, Cordie, Ahmed, Elhadidy, Tamer, Elalfy, Hatem, Farid, Khaled, Elegezy, Mohamed, El-Badrawy, Adel, Neamatallah, Mustafa, Abd Elghafar, Mohamed, Salama, Marwa, AbdAllah, Mohamed, Essam, Mahmoud, El-Shazly, Mostafa, and Esmat, Gamal

Abstract

Limited experimental and clinical evidence suggests a potential role for sofosbuvir/daclatasvir in treating COVID19. We aim to evaluate the efficacy of generic sofosbuvir/daclatasvir in treating COVID-19 patients with pneumonia. This multicenter prospective study involved 174 patients with COVID-19. Patients were randomized into two groups. Group A (96 patients) received sofosbuvir (400 mg)/daclatasvir (60 mg) for 14 days in combination with conventional therapy. Group B (78 patients) received conventional therapy alone. Clinical, laboratory, and radiological data were collected at baseline, after 7, 14, and 28 days of therapy. Primary endpoint was rate of clinical/virological cure. A lower mortality rate was observed in group (A) (14% vs 21%, P = 0.07). After 1 month of therapy, no differences were found in rates of ICU admission, oxygen therapy, or ventilation. Additionally, a statistically significant shorter duration of hospital stay (9% vs 12%, P < 0.01) and a faster achievement of PCR negativity at day 14 (84% versus 47%, P < 0.01) were noticed in group (A). Adding sofosbuvir/daclatasvir to conventional therapy of COVID-19 is promising. Their use is associated with shorter hospital stay, faster PCR negativity and may be reduced mortality. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

26. Impact of successful HCV treatment using direct acting antivirals on recurrence of well ablated hepatocellular carcinoma.

Author

Elbaz, Tamer, Waked, Imam, El-Akel, Wafaa, Shaker, Mohamed Kamal, Abdelaziz, Ashraf Omar, Yousif, Monkez, El-Bendary, Mahmoud, Zaky, Samy, AbdAllah, Mohamed, Hassany, Mohamed, Esmat, Gamal, and Doss, Wahid

Abstract

There are many contradictory studies that dealt with hepatocellular carcinoma (HCC) recurrence rate of well ablated hepatitis C virus (HCV) related HCC. We aim to assess the recurrence rate of previously ablated HCC in patients who received direct acting antiviral (DAA) for their HCV. This is a retrospective data analysis of 523 HCV patients who have a history of successfully ablated HCC and eligible for HCV treatment. Retrieval was done to demographic/clinical data, HCV pretreatment investigations, HCV treatment outcome. Follow up for survival and HCC recurrence was done every 3 months using abdominal ultrasound and alfa-fetoprotein. Mean age was 53.83 years. Sofosbuvir/daclatasvir/ribavirin was the most used regimen (35.4%) with 438 patients (83.7%) achieved sustained virologic response (SVR). The median duration for surveillance was 159 weeks. Hundred and five patients developed recurrent HCC, with a crude recurrence rate of 20.1%. There was no difference between HCV responders and non-responders in crude recurrence rate (p = 0.94) but HCC developed earlier in non-responders (p = <0.01). Recurrence of HCC remains a threat in HCV patients even after achieving an SVR. Implementation of long-term surveillance programs is highly recommended. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

27. Schistosoma mansoniinfection and the occurrence, characteristics, and survival of patients with hepatocellular carcinoma: an observational study over a decade

Author

Shousha, Hend Ibrahim, Abdelaziz, Ashraf Omar, Nabeel, Mohamed Mahmoud, Omran, Dalia Abdelhamid, Abdelmaksoud, Ahmed Hosni, Elbaz, Tamer Mahmoud, Salah, Ayman, Harb, Shady Tarek ElGhazaly, Hosny, Karim Adel, Osman, Ayman, Atef, Mira, Gaber, Abdelazez, Zayed, Naglaa Ali, Yosry, Ayman Abdelhady, and Leithy, Rania

Abstract

ABSTRACTSchistosoma mansoniinfection (SMI) is suspected to be directly and indirectly involved in hepato-carcinogenesis. This study evaluated the association of a previous SMI with hepatocellular carcinoma (HCC) development, patients, tumor characteristics, treatment outcomes, and survival. This observational study included patients with HCC with and without previous SMI who presented to the multidisciplinary HCC clinic, Kasr-Alainy hospital (November 2009 to December 2019). It also included 313 patients with liver cirrhosis without HCC. Clinical and laboratory features of the patients (complete blood count, liver/renal functions , alpha-fetoprotein, and hepatitis B/C status), tumor characteristics (Triphasic CT and/or dynamic MRI), liver stiffness (transient elastography), HCC treatment outcome, and overall survival were studied. This study included 1446 patients with HCC; 688(47.6%) composed group-1, defined by patients having a history of SMI, and 758(52.4%) were in group-2 and without history of SMI. Male sex, smoking, diabetes mellitus, splenomegaly, deteriorated performance status, synthetic liver functions, and platelet count were significantly higher in group-1. The groups did not differ with regard to liver stiffness, tumor characteristics, or the occurrence of post-HCC treatment hepatic decompensation or recurrence. HCC treatment response was better in group-2. Group-1 showed lower sustained virological response to hepatitis C direct-acting antivirals (DAAs) compared with group-2 (60% versus 84.3%, respectively, P = 0.027). Prior SMI was associated with HCC (adjusted odds ratio = 1.589, 95% confidence interval = 1.187–2.127), and it was concluded that it increases the risk of HCC. In addition, it significantly affects the performance status, laboratory characteristics, response to DAAs, and overall survival.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results